Alan Packer


Alan Packer joined the Simons Foundation in 2009 as an associate director of research. He earned his undergraduate degree in biology from Brandeis University and his Ph.D. in cell biology and genetics from the Weill Cornell Graduate School of Medical Sciences in New York City. His graduate work with Rosemary Bachvarova focused on germ cell development using the mouse as a model system. With Debra Wolgemuth at the Columbia University College of Physicians and Surgeons, he carried out postdoctoral work on developmental control genes (HOX genes) and the mechanisms of their regulation in the mouse embryo. In 2000, Packer joined the editorial staff of Nature Genetics, the leading journal in the field of genetics, where he was involved in all aspects of the journal’s production. His responsibilities included overseeing peer review of submitted manuscripts, with an emphasis on the genetics of human disease, as well as commissioning reviews, writing press releases and editorials, updating the journal’s website, and preparing special issues of the journal. He served as acting editor in 2002-2003. During his tenure at Nature Genetics, he established a wide range of contacts in the genetics community through attendance at meetings and visits with scientists in their labs. Packer has also done freelance writing on a number of topics for Nature and other scientific publications.

From this contributor

Explore more from The Transmitter

Headshots of Yale researchers Yong-Hui Jiang and Jiangbing Zhou.

Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions

Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.

By Natalia Mesa
3 June 2026 | 11 min read

What counts as a ‘naturalistic’ behavior?

Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.

By Paul Middlebrooks
3 June 2026 | 1 min read
Research image of brain cells involved with Amyotrophic lateral sclerosis (ALS) illuminated through genetic tools

Allen Institute sets sights on treatments for five brain diseases

The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.

By Calli McMurray
2 June 2026 | 5 min read